Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 346

Do sin stocks really give your portfolio the edge?

Two recent papers looked at the historically strong performance (and recent weak performance) of what are known as ‘sin’ stocks. The analysis found that the stocks’ past outperformance (or alpha) was not as simple as reaping the rewards of a ‘deal with the devil’.

What are sin stocks?

‘Sin’ stocks are usually considered to be those whose activities are dominated by what would be considered unethical or immoral activity, usually alcohol, tobacco, gambling, adult entertainment and weapons.

We looked at two relevant papers covering the returns of such stocks:

  • Blitz, D. and F.J. Fabozzi. Sin Stocks Revisited: Resolving the Sin Stock Anomaly, 2017
  • Jorgensen, A. 'Sin' Stock Exclusions: What is the Impact?, UBS Global Research, October 2019

The data in both papers is drawn from Kenneth French’s data library and covers tobacco, alcohol and weapons.

Note that this approach identifies only the manufacturers of these goods, and indeed only firms for which manufacturing the product is their primary business.

Performance of sin stocks in history

Chart 1 below (from the UBS paper) shows that these stocks had very strong performance from the early 2000s to about 2016 or 2017. In fact, the data show that over the past 43 years, a cap-weighted benchmark of the largest 50 ‘sin’ stocks has outperformed the MSCI World by nearly 5% per year.

Chart 1: Sin stocks performance v benchmark: outperform the benchmark significantly and then sell-off over the last three years

The chart also plots the excess return of a portfolio of the MSCI World without these 50 names, to see what performance drag the portfolio would have had from excluding them. The answer is – very little. In fact, the portfolio of MSCI World, excluding the 50 sin stocks, only underperforms the MSCI World itself by about 6bps (0.06%) per year, as per Table 1.

Table 1: Summary statistics of portfolios of sin stocks, MSCI World (ex-sin stocks) and the MSCI World itself

The reason for this is clear – these stocks only actually represent a small component of the investible universe (a global average of 2.2%). Blitz and Fabozzi (2017) state that the size of these stocks in Developed Markets portfolios is not large: “… the combined weight of the sin sectors averages 2.1% for the United States, 3.5% for Europe, 1.6% for Japan, and 2.2% for global.” The UBS paper also notes that “… the low market capitalisation of these sectors means that, in practical terms, excluding them does not lead to significant change in performance.”

Recently, the outperformance of sin stocks has reversed, with a portfolio of 50 sin stocks down about 6% per year for 2017–2019.

Chart 2 (again from UBS) shows the stocks’ outperformance by broader sector categorisations, over a much longer horizon than Chart 1. The sin stock groupings here are alcohol, tobacco and weapons, which are easier to capture over a long period. All three sectors have participated in this alpha, with tobacco the best. The 1960–1990 period is truly remarkable, with the aggregate sin portfolio creating approximately 16 times the wealth of investing in the broader stock market.

Chart 2: Sin stocks outperformance by sector

Recent performance of sin stocks

As noted, Chart 3 shows that many sin stocks have sold off very strongly over the past three years. It appears the main drivers have been increased regulations, the rise of ‘vaping’ as a smoking alternative, and investors choosing to divest or exclude the stocks for ethical reasons.

Chart 3: Annual outperformance for each sector 2016-2019

Was there ever any alpha?

At first glance, the above charts would suggest that having an aggressive holding in these sectors would have delivered outperformance (alpha). However, the two papers agree conclusively that while apparent in simple excess return calculations, this alpha does not survive analysis when considering common factors such as size, value or momentum.

That is, there is no specific alpha in these names. The alpha is captured by well-known return factors, and so their factor exposure (and performance) could potentially be replicated by a portfolio of other (‘non-sin’) stocks.

The return factors used to capture any alpha (or detect unique insights) stem from the Fama and French class of models. The Blitz and Fabozzi paper, and the UBS analysis, both use the market return itself plus six other return premium factors:

  • Size: smallest stocks over largest stocks, by market cap
  • Value: cheapest stocks over most expensive stocks (measured using Book to Price)
  • Momentum: highest 12-month momentum stocks over lowest 12-month momentum stocks
  • Low beta (or ‘betting against beta’): Low beta stocks over high beta stocks
  • Profitability: highest profit margin stocks over lowest profit margin stocks
  • Investment (or ‘over investment’): lowest asset growth stocks over highest asset growth stocks

No sin in excluding these stocks

The observed outperformance is subsumed by a set of well-known return factors. Among other things, sin stocks seem to be low beta, are smaller than average and don’t seem to have a systematic value or momentum tilt. Sin stocks can be excluded from a portfolio without compromising potential performance.

 

David Walsh is Head of Investments at Realindex Investments, a wholly owned investment management subsidiary of First Sentier Investors, a sponsor of Firstlinks. This article is primarily for information. It discusses ideas that are important to the Realindex investment process and clients but may not be implemented in the ways discussed here.

For more articles and papers from First Sentier Investors, please click here.

 

banner

Most viewed in recent weeks

Why we’re not buying the market yet

The Australian market bounced back last Friday (13th) and Monday (16th) tempting analysts to call the bottom of the coronavirus scare. This is too early as the impact on companies is not yet evident.

How $200 billion is magically created

Australia is in a relatively good position to borrow $200 billion, with the RBA using printed money to buy bonds in the market. The long-term consequences are better than the alternative.

Howard Marks on 'Which way now?'

Howard Marks is the largest investor in the world in distressed securities. What does he think after checking the virus positives and negatives, and how much has he changed his mind in only a few days?

Drawdown reductions needed for retirees - UPDATED POLICY

During the GFC, in the face of rapid falls in super balances, the minimum drawdowns required for pensions were reduced by 50% to help preserve overall retirement savings. It's time for a repeat.

What are the possible economic effects of COVID-19 on the world economy?

In a widely-quoted scenario using estimated attack and fatality rates of coronavirus, about 0.07% of the population of the US dies. That's about 230,000 people, which the market is not ready for.

Note to Australia: be more French in the COVID-19 war

Andrew Baker is well-known as a superannuation consultant. Now working in the UK, he was caught in France with his family and is in lockdown. He worries Australian policy was too slow.

Latest Updates

Economy

Bill Gates: How to make up for lost time on COVID-19

Bill Gates warned the world in 2015 that we were not ready for the next inevitable pandemic, and we ignored him. The Washington Post has provided free access to his updated views.

Hamish Douglass on COVID-19: the three keys to the outlook

Hamish Douglass outlines three important issues in the outbreak of the coronavirus, and describes some consequences which may change businesses and consumers forever. We may never be the same.

Economy

How $200 billion is magically created

Australia is in a relatively good position to borrow $200 billion, with the RBA using printed money to buy bonds in the market. The long-term consequences are better than the alternative.

Investment strategies

Howard Marks on 'Which way now?'

Howard Marks is the largest investor in the world in distressed securities. What does he think after checking the virus positives and negatives, and how much has he changed his mind in only a few days?

Latest from Morningstar

Four stages of a typical bear market - but is this typical?

Bear markets caused by recession fears follow a pattern, but we have never seen anything like coronavirus. If financial stimulus and medicine prove ineffective, all bets are off. 

Economy

COVID-19 executes to a different playbook

The turning point in this crisis will be when the number of new COVID-19 cases starts to decrease. Until then, can we mitigate the damage to businesses and the economy so that we can snap back?

Investment strategies

Why technology stocks are good for the future

Over the long term, the technology sector has a vital role to make the essential transition to a more sustainable global economy and a cleaner planet. We highlight a few names with strong prospects.

SMSF strategies

Avoid complacency with your SMSF's investment strategy

Many trustees of SMSFs have become complacent about vague Investment Strategies, but fund auditors and regulators are paying far more attention. Ensuring your fund complies requires some simple changes.

Sponsors

Alliances

© 2020 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use.
Any general advice or class service prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, has been prepared by without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.